Advertisement

Cost Effectiveness of Pertussis Vaccination in Adults

      Background

      Prior economic analyses have reached disparate conclusions about whether vaccinating adults against pertussis would be cost effective. Newly available data on pertussis incidence were used to evaluate the cost effectiveness of one-time adult vaccination and adult vaccination with decennial boosters.

      Methods

      A Markov model was used to calculate the health benefits, risks, costs, and cost effectiveness of the following strategies: (1) no adult pertussis vaccination, (2) one-time adult vaccination at 20–64 years, and (3) adult vaccination with decennial boosters. The impact of the severity of pertussis illness, vaccine adverse events, and herd immunity on model outcomes were also examined.

      Results

      At a disease incidence of 360 per 100,000, the one-time adult vaccination strategy would prevent 2.8 million cases, and the decennial vaccination strategy would prevent 8.3 million cases. As disease incidence varied from 10 to 500 per 100,000, the one-time adult vaccination strategy was projected to prevent 79,000 to 3.8 million adult pertussis cases, while the decennial vaccination program would prevent 239,000 to 11.4 million cases. A one-time adult vaccination strategy would result in 106 million people vaccinated, or approximately 64% of the adult cohort, for a total program cost of $2.1 billion, while a decennial vaccination strategy would cost $6.7 billion. The one-time and decennial booster vaccination strategies result in cost-effectiveness ratios of <$50,000 per quality-adjusted life year saved if disease incidence in adults were greater than 120 cases per 100,000 population.

      Conclusions

      Routine vaccination of adults aged 20 to 64 years with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis is cost effective if pertussis incidence in this age group is greater than 120 per 100,000 population.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Farizo K.M.
        • Cochi S.L.
        • Zell E.R.
        • Brink E.W.
        • Wassilak S.G.
        • Patriarca P.A.
        Epidemiological features of pertussis in the United States, 1980–1989.
        Clin Infect Dis. 1992; 14: 708-719
        • Yih W.K.
        • Lett S.M.
        • des Vignes F.N.
        • Garrison K.M.
        • Sipe P.L.
        • Marchant C.D.
        The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989–1998.
        J Infect Dis. 2000; 182: 1409-1416
      1. Pertussis—United States, 1997–2000.
        MMWR Morb Mortal Wkly Rep. 2002; 51: 73-76
        • Black S.
        Epidemiology of pertussis.
        Pediatr Infect Dis J. 1997; 16: S85-S89
        • Guris D.
        • Strebel P.M.
        • Bardenheier B.
        • et al.
        Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996.
        Clin Infect Dis. 1999; 28: 1230-1237
        • De Serres G.
        • Shadmani R.
        • Duval B.
        • et al.
        Morbidity of pertussis in adolescents and adults.
        J Infect Dis. 2000; 182: 174-179
        • Thomas P.F.
        • McIntyre P.B.
        • Jalaludin B.B.
        Survey of pertussis morbidity in adults in western Sydney.
        Med J Aust. 2000; 173: 74-76
        • Lee G.M.
        • Lett S.
        • Schauer S.
        • et al.
        Societal costs and morbidity of pertussis in adolescents and adults.
        Clin Infect Dis. 2004; 39: 1572-1580
        • Postels-Multani S.
        • Schmitt H.J.
        • Wirsing von Konig C.H.
        • Bock H.L.
        • Bogaerts H.
        Symptoms and complications of pertussis in adults.
        Infection. 1995; 23: 139-142
        • Purdy K.W.
        • Hay J.W.
        • Botteman M.F.
        • Ward J.I.
        Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost–benefit analysis.
        Clin Infect Dis. 2004; 39: 20-28
        • Lee G.M.
        • Lebaron C.
        • Murphy T.V.
        • Lett S.
        • Schauer S.
        • Lieu T.A.
        Pertussis in adolescents and adults: should we vaccinate?.
        Pediatrics. 2005; 115: 1675-1684
        • Ward J.I.
        • Cherry J.D.
        • Chang S.J.
        • et al.
        Efficacy of an acellular pertussis vaccine among adolescents and adults.
        N Engl J Med. 2005; 353: 1555-1563
        • Cortese M.M.
        • Baughman A.
        • Brown K.
        • Srivastava P.
        A “new age” for pertussis prevention in the United States: seizing opportunities through adult vaccination.
        Am J Prev Med. 2007; 32: 177-185
      2. http://www.census.gov/popest/states/NST-ann-est.html.

        • Strebel P.
        • Nordin J.
        • Edwards K.
        • et al.
        Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996.
        J Infect Dis. 2001; 183: 1353-1359
        • Nennig M.E.
        • Shinefield H.R.
        • Edwards K.M.
        • Black S.B.
        • Fireman B.H.
        Prevalence and incidence of adult pertussis in an urban population.
        JAMA. 1996; 275: 1672-1674
        • Mink C.M.
        • Cherry J.D.
        • Christenson P.
        • et al.
        A search for Bordetella pertussis infection in university students.
        Clin Infect Dis. 1992; 14: 464-471
        • Centers for Disease Control and Prevention
        Pertussis—United States, 1997–2000.
        JAMA. 2002; 287: 977-979
        • Ward J.
        The APERT Study. 2002 (Paper presented at the National Consensus Conference on Pertussis, May 25–28, Toronto)
        • Ward J.I.
        • APERT Study Group
        Pertussis epidemiology and acellular pertussis vaccine efficacy in older children: NIH APERT Multicenter Pertussis Trial. 2001 (Paper presented at the Pediatric Academic Societies Annual Meeting, Baltimore MD)
        • Jenkinson D.
        Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study.
        Br Med J (Clin Res Ed). 1988; 296: 612-614
        • Lambert H.J.
        Epidemiology of a small pertussis outbreak in Kent County, Michigan.
        Public Health Rep. 1965; 80: 365-367
        • Cattaneo L.A.
        • Reed G.W.
        • Haase D.H.
        • Wills M.J.
        • Edwards K.M.
        The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years.
        J Infect Dis. 1996; 173: 1256-1259
        • Ramsay M.E.
        • Farrington C.P.
        • Miller E.
        Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods.
        Epidemiol Infect. 1993; 111: 41-48
        • Gold M.R.
        • Siegel J.E.
        • Russell L.B.
        • Weinstein M.C.
        Cost-effectiveness in health and medicine. Oxford University Press, New York1996
        • Van der Wielen M.
        • Van Damme P.
        • Joossens E.
        • Francois G.
        • Meurice F.
        • Ramalho A.
        A randomised controlled trial with a diphtheria–tetanus–acellular pertussis (dTap) vaccine in adults.
        Vaccine. 2000; 18: 2075-2082
        • Halperin S.A.
        • Smith B.
        • Russell M.
        • et al.
        An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
        Vaccine. 2000; 18: 1312-1319
        • Halperin S.A.
        • Smith B.
        • Russell M.
        • et al.
        Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
        Pediatr Infect Dis J. 2000; 19: 276-283
        • Rennels M.B.
        Extensive swelling reactions occurring after booster doses of diphtheria–tetanus–acellular pertussis vaccines.
        Semin Pediatr Infect Dis. 2003; 14: 196-198
        • Rennels M.B.
        • Deloria M.A.
        • Pichichero M.E.
        • et al.
        Extensive swelling after booster doses of acellular pertussis–tetanus–diphtheria vaccines.
        Pediatrics. 2000; 105: e12
        • Jackson L.A.
        • Carste B.A.
        • Malais D.
        • Froeschle J.
        Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids.
        Pediatr Infect Dis J. 2002; 21: 781-786
        • Bohlke K.
        • Davis R.L.
        • Marcy S.M.
        • et al.
        Risk of anaphylaxis after vaccination of children and adolescents.
        Pediatrics. 2003; 112: 815-820
        • Singleton J.A.
        • Greby S.M.
        • Wooten K.G.
        • Walker F.J.
        • Strikas R.
        Influenza, pneumococcal, and tetanus toxoid vaccination of adults—United States, 1993–7.
        MMWR CDC Surveill Summ. 2000; 49: 39-62
        • Van Rie A.
        • Hethcote H.W.
        Adolescent and adult pertussis vaccination: computer simulations of five new strategies.
        Vaccine. 2004; 22: 3154-3165
        • Deen J.L.
        • Mink C.A.
        • Cherry J.D.
        • et al.
        Household contact study of Bordetella pertussis infections.
        Clin Infect Dis. 1995; 21: 1211-1219
        • Crowcroft N.S.
        • Booy R.
        • Harrison T.
        • et al.
        Severe and unrecognised: pertussis in UK infants.
        Arch Dis Child. 2003; 88: 802-806
        • Bisgard K.M.
        • Pascual F.B.
        • Ehresmann K.R.
        • et al.
        Infant pertussis: who was the source?.
        Pediatr Infect Dis J. 2004; 23: 985-989
        • Bourgeois F.
        • Goldmann D.A.
        • Ross-Degnan D.
        • Hibberd P.
        • Lee G.M.
        Health service utilization and economic burden of daycare-associated illness. 2006 (Abstract presented at the Pediatric Academic Societies’ Annual Meeting, San Francisco CA)
      3. Centers for Medicare & Medicaid Services (CMS) HHS. Medicare Program: changes to the hospital inpatient prospective payment systems and rates and costs of graduate medical education: fiscal year 2002 rates; Provisions of the Balanced Budget Refinement Act of 1999; and Provisions of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000: Department of Health and Human Services, Centers for Medicare & Medicaid Services, August 1, 2001. Vol. 66, No. 148, 42 CFR Parts 405, 410, 412.

        • Morris M.
        • Tang S.
        Pediatric Service Utilization, Fees and Managed Care Arrangements, 2001 report based on 1999 data. American Academy of Pediatrics, Elk Grove Village2001
      4. NASA. Available at: http://www.jsc.nasa.gov/bu2/inflateGDP.html (Accessed October 30, 2005).

      5. U.S. Census Bureau. Available at: www.census.gov/hhes/income/income00/inctab7.html.

      6. Arrow Pharmaceuticals. Available at: http://www.arrowpharma.com/about.cfm.

      7. Aventis Pasteur—Canada, 1-416-667-2700.

      8. Bundaberg & District, Division of General Practice. Available at: http://www.widebaydgp.org.au/News/newslett/Sept-Oct2002a.pdf.

      9. http://www.worldwidevaccines.com/by_country/gsk_vaccines.asp.

        • Zhou W.
        • Pool V.
        • Iskander J.K.
        • et al.
        Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)—United States, 1991–2001.
        MMWR Surveill Summ. 2003; 52: 1-24
        • Lee
        • Salomon J.A.
        • LeBaron C.W.
        • Lieu T.A.
        Health-state valuations for pertussis: methods for valuing short-term health states.
        Health Qual Life Outcomes. 2005; 3 (gm): 17
        • Tozzi A.E.
        • Rava L.
        • Ciofi degli Atti M.L.
        • Salmaso S.
        Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life.
        Pediatrics. 2003; 112: 1069-1075
        • Birkebaek N.H.
        • Kristiansen M.
        • Seefeldt T.
        • et al.
        Bordetella pertussis and chronic cough in adults.
        Clin Infect Dis. 1999; 29: 1239-1242
      10. http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm#adult.

        • Stone P.W.
        • Teutsch S.
        • Chapman R.H.
        • Bell C.
        • Goldie S.J.
        • Neumann P.J.
        Cost-utility analyses of clinical preventive services: published ratios, 1976–1997.
        Am J Prev Med. 2000; 19: 15-23
        • Chapman R.H.
        • Stone P.W.
        • Sandberg E.A.
        • Bell C.
        • Neumann P.J.
        A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies.
        Med Decis Making. 2000; 20: 451-467
        • Pignone M.
        • Saha S.
        • Hoerger T.
        • Mandelblatt J.
        Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S..
        Ann Intern Med. 2002; 137 (Preventive Services Task Force): 96-104
        • Winkelmayer W.C.
        • Weinstein M.C.
        • Mittleman M.A.
        • Glynn R.J.
        • Pliskin J.S.
        Health economic evaluations: the special case of end-stage renal disease treatment.
        Med Decis Making. 2002; 22: 417-430
      11. TreeAge Pro 2005 Suite. TreeAge Software, Inc, Williamstown MA2005 ([computer program])